Oramed Pharmaceuticals Inc (ORMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oramed Pharmaceuticals Inc (ORMP) has a cash flow conversion efficiency ratio of -0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.99 Million) by net assets ($202.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oramed Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Oramed Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Oramed Pharmaceuticals Inc carry for a breakdown of total debt and financial obligations.
Oramed Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oramed Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Novem Group S.A.
XETRA:NVM
|
0.229x |
|
Wonik Corporation
KQ:032940
|
0.005x |
|
CPI Card Group Inc
NASDAQ:PMTS
|
-0.389x |
|
Peak Minerals Ltd
AU:PUA
|
-1.262x |
|
Samsung Pharm
KO:001360
|
-0.013x |
|
Ba Ria Vung Tau House Development JSC
VN:HDC
|
-0.001x |
|
Nordic Halibut AS
OL:NOHAL
|
-0.101x |
|
Shanghai Huayi Group Corp Ltd B
SHG:900909
|
-0.076x |
Annual Cash Flow Conversion Efficiency for Oramed Pharmaceuticals Inc (2005–2024)
The table below shows the annual cash flow conversion efficiency of Oramed Pharmaceuticals Inc from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see ORMP stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $145.35 Million | $-8.41 Million | -0.058x | +8.43% |
| 2023-12-31 | $162.89 Million | $-10.29 Million | -0.063x | +66.71% |
| 2022-12-31 | $151.16 Million | $-28.70 Million | -0.190x | -4.45% |
| 2021-12-31 | $116.52 Million | $-21.18 Million | -0.182x | +51.95% |
| 2020-12-31 | $32.88 Million | $-12.44 Million | -0.378x | +43.30% |
| 2019-12-31 | $19.39 Million | $-12.94 Million | -0.667x | -41.64% |
| 2018-12-31 | $31.11 Million | $-14.66 Million | -0.471x | -55.43% |
| 2017-12-31 | $19.24 Million | $-5.83 Million | -0.303x | -270.53% |
| 2016-12-31 | $26.19 Million | $4.66 Million | 0.178x | +189.22% |
| 2015-12-31 | $24.83 Million | $-4.95 Million | -0.199x | -1.82% |
| 2014-12-31 | $20.79 Million | $-4.07 Million | -0.196x | +53.15% |
| 2013-12-31 | $8.13 Million | $-3.40 Million | -0.418x | +31.45% |
| 2012-12-31 | $3.78 Million | $-2.30 Million | -0.609x | -36.17% |
| 2011-12-31 | $3.72 Million | $-1.67 Million | -0.447x | +73.81% |
| 2010-12-31 | $830.27K | $-1.42 Million | -1.708x | -108.25% |
| 2009-12-31 | $2.75 Million | $-2.25 Million | -0.820x | -105.12% |
| 2008-12-31 | $4.59 Million | $-1.84 Million | -0.400x | +66.42% |
| 2007-12-31 | $513.00K | $-611.00K | -1.191x | -242.52% |
| 2006-12-31 | $-432.72K | $-361.61K | 0.836x | -7.39% |
| 2005-12-31 | $-44.81K | $-40.44K | 0.902x | -- |
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for C… Read more